Evaxion Biotech (NASDAQ:EVAX) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.21) by 104.76 percent. This is a 125 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $7.492 million which beat the analyst consensus estimate of $2.500 million by 199.68 percent. This is a 148.33 percent increase over sales of $3.017 million the same period last year.